These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 32024657)

  • 1. Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses.
    Wallach JD; Wang K; Zhang AD; Cheng D; Grossetta Nardini HK; Lin H; Bracken MB; Desai M; Krumholz HM; Ross JS
    BMJ; 2020 Feb; 368():l7078. PubMed ID: 32024657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.
    Dahabreh IJ; Economopoulos K
    Clin Trials; 2008; 5(2):116-20. PubMed ID: 18375649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.
    Singh S; Loke YK; Furberg CD
    JAMA; 2007 Sep; 298(10):1189-95. PubMed ID: 17848653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.
    Nissen SE; Wolski K
    Arch Intern Med; 2010 Jul; 170(14):1191-1201. PubMed ID: 20656674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term risk of rosiglitazone on cardiovascular events - a systematic review and meta-analysis.
    Cheng D; Gao H; Li W
    Endokrynol Pol; 2018; 69(4):381-394. PubMed ID: 29952413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in people with stroke or transient ischaemic attack.
    Liu J; Wang LN
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD010693. PubMed ID: 29197071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
    Nissen SE; Wolski K
    N Engl J Med; 2007 Jun; 356(24):2457-71. PubMed ID: 17517853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death.
    Diamond GA; Bax L; Kaul S
    Ann Intern Med; 2007 Oct; 147(8):578-81. PubMed ID: 17679700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibiotics for secondary prevention of coronary heart disease.
    Sethi NJ; Safi S; Korang SK; Hróbjartsson A; Skoog M; Gluud C; Jakobsen JC
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD003610. PubMed ID: 33704780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis.
    Hudson J; Cruickshank M; Quinton R; Aucott L; Aceves-Martins M; Gillies K; Bhasin S; Snyder PJ; Ellenberg SS; Grossmann M; Travison TG; Gianatti EJ; van der Schouw YT; Emmelot-Vonk MH; Giltay EJ; Hackett G; Ramachandran S; Svartberg J; Hildreth KL; Groti Antonic K; Brock GB; Tenover JL; Tan HM; Kong CHC; Tan WS; Marks LS; Ross RJ; Schwartz RS; Manson P; Roberts S; Andersen MS; Magnussen LV; Hernández R; Oliver N; Wu F; Dhillo WS; Bhattacharya S; Brazzelli M; Jayasena CN
    Lancet Healthy Longev; 2022 Jun; 3(6):e381-e393. PubMed ID: 35711614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rosiglitazone: can meta-analysis accurately estimate excess cardiovascular risk given the available data? Re-analysis of randomized trials using various methodologic approaches.
    Friedrich JO; Beyene J; Adhikari NK
    BMC Res Notes; 2009 Jan; 2():5. PubMed ID: 19134216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Was there really any evidence that rosiglitazone increased the risk of myocardial infarction or death from cardiovascular causes?
    Stone JC; Furuya-Kanamori L; Barendregt JJ; Doi SA
    Pharmacoepidemiol Drug Saf; 2015 Mar; 24(3):223-7. PubMed ID: 25515780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack.
    Liu J; Wang LN
    Cochrane Database Syst Rev; 2015 Oct; (10):CD010693. PubMed ID: 26511368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews.
    Sutcliffe P; Connock M; Gurung T; Freeman K; Johnson S; Kandala NB; Grove A; Gurung B; Morrow S; Clarke A
    Health Technol Assess; 2013 Sep; 17(43):1-253. PubMed ID: 24074752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies.
    Loke YK; Kwok CS; Singh S
    BMJ; 2011 Mar; 342():d1309. PubMed ID: 21415101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map.
    Zhu J; Yu X; Zheng Y; Li J; Wang Y; Lin Y; He Z; Zhao W; Chen C; Qiu K; Wu J
    Lancet Diabetes Endocrinol; 2020 Mar; 8(3):192-205. PubMed ID: 32006518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exercise-based cardiac rehabilitation for chronic heart failure: the EXTRAMATCH II individual participant data meta-analysis.
    Taylor RS; Walker S; Ciani O; Warren F; Smart NA; Piepoli M; Davos CH
    Health Technol Assess; 2019 May; 23(25):1-98. PubMed ID: 31140973
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.